181 related articles for article (PubMed ID: 16479341)
1. Does familial non-medullary thyroid cancer adversely affect survival?
Triponez F; Wong M; Sturgeon C; Caron N; Ginzinger DG; Segal MR; Kebebew E; Duh QY; Clark OH
World J Surg; 2006 May; 30(5):787-93. PubMed ID: 16479341
[TBL] [Abstract][Full Text] [Related]
2. Familial non-medullary thyroid cancer: a matched-case control study.
Maxwell EL; Hall FT; Freeman JL
Laryngoscope; 2004 Dec; 114(12):2182-6. PubMed ID: 15564841
[TBL] [Abstract][Full Text] [Related]
3. Is familial non-medullary thyroid carcinoma more aggressive than sporadic thyroid cancer? A multicenter series.
Alsanea O; Wada N; Ain K; Wong M; Taylor K; Ituarte PH; Treseler PA; Weier HU; Freimer N; Siperstein AE; Duh QY; Takami H; Clark OH
Surgery; 2000 Dec; 128(6):1043-50;discussion 1050-1. PubMed ID: 11114641
[TBL] [Abstract][Full Text] [Related]
4. Familial nonmedullary thyroid carcinoma characterized by multifocality and a high recurrence rate in a large study population.
Uchino S; Noguchi S; Kawamoto H; Yamashita H; Watanabe S; Yamashita H; Shuto S
World J Surg; 2002 Aug; 26(8):897-902. PubMed ID: 11965446
[TBL] [Abstract][Full Text] [Related]
5. In patients with thyroid cancer of follicular cell origin, a family history of nonmedullary thyroid cancer in one first-degree relative is associated with more aggressive disease.
Mazeh H; Benavidez J; Poehls JL; Youngwirth L; Chen H; Sippel RS
Thyroid; 2012 Jan; 22(1):3-8. PubMed ID: 22136209
[TBL] [Abstract][Full Text] [Related]
6. Familial non-medullary thyroid carcinoma displays the features of clinical anticipation suggestive of a distinct biological entity.
Capezzone M; Marchisotta S; Cantara S; Busonero G; Brilli L; Pazaitou-Panayiotou K; Carli AF; Caruso G; Toti P; Capitani S; Pammolli A; Pacini F
Endocr Relat Cancer; 2008 Dec; 15(4):1075-81. PubMed ID: 18832444
[TBL] [Abstract][Full Text] [Related]
7. Familial history of non-medullary thyroid cancer is an independent prognostic factor for tumor recurrence in younger patients with conventional papillary thyroid carcinoma.
Lee YM; Yoon JH; Yi O; Sung TY; Chung KW; Kim WB; Hong SJ
J Surg Oncol; 2014 Feb; 109(2):168-73. PubMed ID: 24132694
[TBL] [Abstract][Full Text] [Related]
8. Familial Non-Medullary Thyroid Cancer Represents an Independent Risk Factor for Increased Cancer Aggressiveness: A Retrospective Analysis of 74 Families.
Tavarelli M; Russo M; Terranova R; Scollo C; Spadaro A; Sapuppo G; Malandrino P; Masucci R; Squatrito S; Pellegriti G
Front Endocrinol (Lausanne); 2015; 6():117. PubMed ID: 26284028
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics and outcome of familial nonmedullary thyroid cancer: a retrospective controlled study.
Robenshtok E; Tzvetov G; Grozinsky-Glasberg S; Shraga-Slutzky I; Weinstein R; Lazar L; Serov S; Singer J; Hirsch D; Shimon I; Benbassat C
Thyroid; 2011 Jan; 21(1):43-8. PubMed ID: 20954815
[TBL] [Abstract][Full Text] [Related]
10. Familial nonmedullary thyroid carcinoma.
Mazeh H; Sippel RS
Thyroid; 2013 Sep; 23(9):1049-56. PubMed ID: 23734600
[TBL] [Abstract][Full Text] [Related]
11. Is Familial Nonmedullary Thyroid Cancer A More Aggressive Type of Thyroid Cancer?
Muallem Kalmovich L; Jabarin B; Koren S; Or K; Marcus E; Tkacheva I; Benbassat C; Steinschneider M
Laryngoscope; 2021 Feb; 131(2):E677-E681. PubMed ID: 32761812
[TBL] [Abstract][Full Text] [Related]
12. Familial non-medullary thyroid carcinoma: pathology review in 27 affected cases from 13 French families.
Leprat F; Bonichon F; Guyot M; Trouette H; Trojani M; Vergnot V; Longy M; Belleannée G; de Mascarel A; Roger P
Clin Endocrinol (Oxf); 1999 May; 50(5):589-94. PubMed ID: 10468924
[TBL] [Abstract][Full Text] [Related]
13. Allelic loss of susceptibility loci and the occurrence of BRAF and RAS mutations in patients with familial non-medullary thyroid cancer.
Na KY; Kim RM; Song EM; Lee JH; Lee J; Soh EY
J Surg Oncol; 2012 Jan; 105(1):10-4. PubMed ID: 21826673
[TBL] [Abstract][Full Text] [Related]
14. Disease-free survival in papillary and follicular thyroid carcinoma. Comparison between UICC 5th and 7th classifications of T stage, and the prognostic value of primary tumour size.
Meixner M; Hellmich M; Dietlein M; Kobe C; Schicha H; Schmidt M
Nuklearmedizin; 2013; 52(3):71-80. PubMed ID: 23483137
[TBL] [Abstract][Full Text] [Related]
15. Clinical and Genetic Features of a Large Monocentric Series of Familial Non-Medullary Thyroid Cancers.
Cirello V; Colombo C; Karapanou O; Pogliaghi G; Persani L; Fugazzola L
Front Endocrinol (Lausanne); 2020; 11():589340. PubMed ID: 33488516
[TBL] [Abstract][Full Text] [Related]
16. Familial non-medullary thyroid carcinoma (FNMTC): analysis of fPTC/PRN, NMTC1, MNG1 and TCO susceptibility loci and identification of somatic BRAF and RAS mutations.
Cavaco BM; Batista PF; Martins C; Banito A; do Rosário F; Limbert E; Sobrinho LG; Leite V
Endocr Relat Cancer; 2008 Mar; 15(1):207-15. PubMed ID: 18310288
[TBL] [Abstract][Full Text] [Related]
17. An evidence-based approach to familial nonmedullary thyroid cancer: screening, clinical management, and follow-up.
Sippel RS; Caron NR; Clark OH
World J Surg; 2007 May; 31(5):924-33. PubMed ID: 17429563
[TBL] [Abstract][Full Text] [Related]
18. A Greek family with a follicular variant of familial papillary thyroid carcinoma: TCO, MNG1, fPTC/PRN, and NMTC1 excluded as susceptibility loci.
Tsilchorozidou T; Vafiadou E; Yovos JG; Romeo G; McKay J; Lesueur F; Bonora E
Thyroid; 2005 Dec; 15(12):1349-54. PubMed ID: 16405407
[TBL] [Abstract][Full Text] [Related]
19. Risk of thyroid cancer in first-degree relatives of patients with non-medullary thyroid cancer by histology type and age at diagnosis: a joint study from five Nordic countries.
Fallah M; Pukkala E; Tryggvadottir L; Olsen JH; Tretli S; Sundquist K; Hemminki K
J Med Genet; 2013 Jun; 50(6):373-82. PubMed ID: 23585692
[TBL] [Abstract][Full Text] [Related]
20. FAMILIAL NON-MEDULLARY THYROID CARCINOMA.
Guda BB; Komisarenko II; Ostafiichuk MV; Tronko MD
Exp Oncol; 2023 Jun; 45(1):70-78. PubMed ID: 37417280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
